Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus.
10.4093/dmj.2012.36.3.230
- Author:
Eun Yeong CHOE
1
;
Yong Ho LEE
;
Byung Wan LEE
;
Eun Seok KANG
;
Bong Soo CHA
;
Hyun Chul LEE
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. bwanlee@yuhs.ac
- Publication Type:Original Article
- Keywords:
Basal insulin;
Diabetes mellitus, type 2;
Insulin, rapid-acting
- MeSH:
Aged;
Diabetes Mellitus, Type 2;
Glucose;
Hemoglobins;
Humans;
Hypoglycemic Agents;
Insulin;
Insulin, Long-Acting;
Insulin, Short-Acting;
Logistic Models;
Retrospective Studies;
Serum Albumin;
Sulfonylurea Compounds;
Insulin Glargine
- From:Diabetes & Metabolism Journal
2012;36(3):230-236
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The present study investigates the efficacy in glycemic control by adding once-a-day glulisine to glargine as a basal plus regimen and factors influencing glycemic control with the basal plus regimen in Korean subjects with type 2 diabetes. METHODS: In the present retrospective study, subjects previously treated with the basal plus regimens for at least 6 months were reviewed. Changes in glycemic profiles and clinical parameters were evaluated. RESULTS: A total of 87 subjects were ultimately enrolled in this study. At baseline, mean glycated hemoglobin (A1c) and glycated albumin were 8.5% (8.0% to 9.6%) and 25.2+/-7.6%, respectively. After treatment with the basal plus regimen, patients had significant reductions of A1c at 6 months (0.8+/-0.1%, P<0.001) and their postprandial glucose levels were decreased by 48.7+/-10.3 mg/dL (P<0.001). Multiple logistic regression showed old age (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.02 to 1.55), high initial A1c (OR, 22.21; 95% CI, 2.44 to 201.78), and lower amounts of glargine (OR, 0.85; 95% CI, 0.76 to 0.99), and glimepiride (OR, 0.23; 95% CI, 0.06 to 0.93) at baseline were independently associated with good responders whose A1c reduction was more than 0.5%. CONCLUSION: The authors suggest a basal plus regimen may be effective in reducing glucose levels of subjects with old age, high initial A1c, and patients on low doses of glimepiride and glargine. Despite the use of high doses of hypoglycemic agents, elderly patients with poorly-controlled diabetes are preferred for early initiation of the basal plus regimen.
